BerGenBio is a startup based in Norway, most recent round Acquired, 2 tracked investors.
BerGenBio is a company headquartered in Norway. BerGenBio has been acquired. Brouky records 2 investors associated with the company.
BerGenBio developed first-in-class AXL inhibitors targeting aggressive diseases, particularly in oncology, before merging with Oncoinvent ASA in 2025.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.